Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis is a research paper published in Alzheimer s & Dementia (2024). On theSindex it has a DataRank of 0.165. It has been cited 2 times, with 1 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →National Institute of Mental Health
Grant: 2R25MH101076‐06A1
National Institute on Aging
Grant: 2P01AG051449‐06
National Institute on Aging
Grant: R01AG068990
National Institutes of Health
Grant: U01 AG024904
U.S. Department of Defense
Grant: W81XWH‐12‐2‐0012
NIA NIH HHS
Grant: R01 AG062268
NIMH NIH HHS
Grant: R01 MH120794
Department of Defense
Grant: W81XWH-12-2-0012
NIA NIH HHS
Grant: U01 AG079850
NIMH NIH HHS
Grant: 2R25MH101076-06A1
NIA NIH HHS
Grant: 2P01AG051449-06
NIMH NIH HHS
Grant: R25 MH101076
NIA NIH HHS
Grant: P01 AG051449
National Institutes of Health
Grant: 5R01AG068990-05
Developing novel cognitive and neuroimaging markers of early Alzheimers disease pathologies
National Institutes of Health
Grant: 3P01AG051449-05S1
Somatic Activation of Retrotransposition: A new Molecular Mechanism of Aging?
National Institutes of Health
Grant: 1U01AG024904-01
Alzheimers Disease Neuroimaging Initiative
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 3R25MH101076-07S2
Promoting Research Training During Psychiatry Residency
Fujirebio US
Servier
Alzheimer's Association
Canadian Institutes of Health Research
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
Lumosity; Lundbeck; Merck & Co., Inc.
Takeda Pharmaceutical Company
Alzheimer's Association
Biogen
Bristol-Myers Squibb
Eisai Inc.
Janssen Alzheimer Immunotherapy Research & Development, LLC.
Neurotrack Technologies
Alzheimer's Drug Discovery Foundation
Araclon Biotech
BioClinica
Piramal Imaging
EuroImmun
F. Hoffmann-La Roche Ltd
Meso Scale Diagnostics, LLC.
CereSpir, Inc.
Cogstate
Genentech, Inc.
IXICO Ltd.
Johnson & Johnson Pharmaceutical Research & Development LLC.
Alzheimer's Drug Discovery Foundation
BioClinica, Inc.
Bristol-Myers Squibb Company
CIHR
GE Healthcare
Genentech
National Institute of Biomedical Imaging and Bioengineering
NeuroRx Research
Fujirebio
NIBIB NIH HHS
Novartis Pharmaceuticals Corporation
Transition Therapeutics
FWCI
0.54
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals